Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by socksnblonds642on Jan 15, 2024 10:51am
270 Views
Post# 35826885

RE:RE:Update on Phase II Bladder Cancer

RE:RE:Update on Phase II Bladder CancerThis release is pretty much irrelevant to us. Likely for PP purposes only. All good info. The numbers look great. We're all here and excited because of the results like this.  I am wondering where the BTD submission is. Results are more than good enough to submit. There are enough evaluable patients for the FDA to review. I'd like to see an update telling us where they are with BTD. I personally would NOT participate in a PP unless I knew the FDA had the data as requested and was reviewing it. We've all read that the FDA had given them guidance on how to present the data. I'd want to know what if any criteria is still missing. 

<< Previous
Bullboard Posts
Next >>